Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The main aim of this study is to observe correction of the hemoglobin level in the patients
under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or
a lymphoma or a myeloma.
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer